Objective: To investigate the influence of chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) on male health.
Methods: We conducted investigations among 200 cases of CP/CPPS, aged 20 -59 years and randomly selected from 650 out-patients, using an anonymous questionnaire including such items as the patients'age, height, body weight, disease duration and treatment, the results of EPS and semen determinations, and the scores on NIH-CPSI, IIEF-5 and Symptom Checklist (SCL-90).
Results: According to the 198 valid questionnaires collected, CPSI scores showed 56 (28.3%) cases to be mild, 98 (49.5%) moderate and 44 (22.2%) severe. Sperm density and motility (grade a + b) were reduced in 38 (19.2%) and 47 (23.7%) cases, respectively. IIEF-5 revealed ED in 41 (20.7%) cases, of which 58.5% were mild. Psychological abnormality was found in 94 (47.5%) cases, including anxiety, depression, sensitiveness and so on. NIH-CPSI scores were positively correlated with psychological symptoms and ED (r = 0.25, P < 0.05; r = 0.12, P < 0.05), but not significantly related with sperm density and motility (P > 0.05).
Conclusion: The influence of CP/CPPS is obvious on male psychology but mild on penile erection and not significant on semen. Integrated physiological and psychological therapy is recommended for the treatment of CP/CPPS.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Safety and efficacy of extracorporeal shockwave therapy on chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Prostate Int
December 2024
Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Purpose: This study aimed to investigate the efficacy and safety of extracorporeal shock wave therapy (ESWT) over an 8-week period in individuals diagnosed with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) compared to a control group.
Materials And Methods: This prospective, double-blind, placebo-controlled study enrolled 46 participants diagnosed with CP/CPPS, who were randomly assigned to either the treatment group or the control group in a 2:1 ratio. In the treatment group, ESWT was administered at the perineum once a week for 8 weeks.
Effectiveness of Extended-Release Bupropion and Duloxetine on Pelvic Pain and Sexual Function among Patients with Chronic Prostatitis/Chronic Pelvic Pain.
Adv Biomed Res
October 2024
Department of Psychiatry, Psychosomatic Research Center, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: This study aimed to compare the efficacy of the two antidepressants, duloxetine and bupropion, on pelvic pain in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Materials And Methods: This single-blind clinical trial was conducted on 68 CP/CPPS patients. The patients with CP/CPPS received either an extended-release formulation of 150 mg/day bupropion (bupropion group) or duloxetine 30 mg/day for 12 weeks (duloxetine group).
Relationship of Sex and Diagnosis With Symptoms and Illness Impact in Urologic Chronic Pelvic Pain; A Mapp Network Analysis.
Neurourol Urodyn
December 2024
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Objective: To assess differences in clinical presentation and illness impact in men and women presenting with urologic chronic pelvic pain syndrome (UCPPS) and between men diagnosed with interstitial cystitis/bladder pain syndrome (IC/BPS) or chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Methods: 356 men and 605 women from six sites across the United States were assessed using a comprehensive set of demographic, symptom, and illness impact measures. Multivariable regression analyses examined differences between men and women and between men previously diagnosed with CP/CPPS or IC/BPS.
NLRP3 inflammasome in expressed prostatic secretions as a potential biomarker of chronic prostatitis/chronic pelvic pain syndrome.
Adv Clin Exp Med
December 2024
Department of Urology, Tianjin Medical University Baodi Hospital, China.
Background: Pyroptosis has been implicated in the progression of chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS).
Objectives: The present study was performed to explore the diagnostic value of the levels of the pyroptosis-related protein nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3 (NLRP3) inflammasome in the expressed prostatic secretions (EPS) of patients with CP.
Material And Methods: A total of 167 CP patients, including 85 National Institutes of Health (NIH)-IIIA CP patients and 82 NIH-IIIB CP patients, as well as 80 benign prostatic hyperplasia (BPH) patients and 80 healthy controls, were enrolled.
Comparative efficacy of non-pharmacological management for chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis protocol.
BMJ Open
December 2024
Department of Acupuncture and Neurology, Guangan'men Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has posed a significant burden on affected individuals and healthcare systems. While pharmacological treatments are commonly used, non-pharmacological management strategies have gained attention for their potential benefits in improving CP/CPPS symptoms. However, the comparative efficacy of these non-pharmacological interventions remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!